Literature DB >> 28245467

Hospitalizations Due to Cirrhosis: Clinical Aspects in a Large Cohort of Italian Patients and Cost Analysis Report.

Marco Di Pascoli1, Elena Ceranto, Paolo De Nardi, Daniele Donato, Angelo Gatta, Paolo Angeli, Patrizia Pontisso.   

Abstract

BACKGROUND AND AIM: Liver cirrhosis is characterized by high morbidity and mortality rates. This study was addressed to evaluate the epidemiological and economic impact of cirrhosis on hospitalizations in a large population in Italy.
METHODS: Epidemiological analysis was performed using hospital discharge sheets of 57,720 hospitalizations due to liver disease from 2006 to 2008, selected from the Veneto regional archive. In a sample of 100 randomly selected hospitalizations, a detailed cost analysis was performed and a comparison was made with sets of patients admitted for heart failure (HF) and chronic obstructive pulmonary disease (COPD).
RESULTS: Among patients with cirrhosis, ascites emerged as the most frequent cause of admission, followed by hepatic encephalopathy, hepatocellular carcinoma, and upper gastrointestinal bleeding. Encephalopathy and ascites were the complications with the highest rates of readmission. The detailed cost analysis of hospitalizations revealed that economic expenses in the set of patients admitted for cirrhosis were about 30% higher than those for patients admitted for HF or COPD, mainly due to the longer duration of hospitalization.
CONCLUSIONS: Cirrhosis has a relevant epidemiological and economic impact on hospitalizations and preventive strategies for its clinical management are warranted.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Epidemiology; Healthcare costs; Hospitalization; Liver cirrhosis

Mesh:

Year:  2017        PMID: 28245467     DOI: 10.1159/000458722

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  8 in total

Review 1.  Outcomes in Clinical Trials Evaluating Interventions for the Prevention and Treatment of Hepatic Encephalopathy.

Authors:  Lise L Gluud; Rebecca Jeyaraj; Marsha Y Morgan
Journal:  J Clin Exp Hepatol       Date:  2019-02-15

Review 2.  Hepatic encephalopathy.

Authors:  Dieter Häussinger; Radha K Dhiman; Vicente Felipo; Boris Görg; Rajiv Jalan; Gerald Kircheis; Manuela Merli; Sara Montagnese; Manuel Romero-Gomez; Alfons Schnitzler; Simon D Taylor-Robinson; Hendrik Vilstrup
Journal:  Nat Rev Dis Primers       Date:  2022-06-23       Impact factor: 65.038

3.  Incidence and predictors of 30-day hospital readmissions for liver cirrhosis: insights from the United States National Readmissions Database.

Authors:  Sushil Kumar Garg; Hemant Goyal; Itegbemie Obaitan; Pir Ahmad Shah; Shashank Sarvepalli; Loretta Lynn Jophlin; Dupinder Singh; Sumeet Asrani; Patrick S Kamath; Michael D Leise
Journal:  Ann Transl Med       Date:  2021-07

4.  Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin.

Authors:  Guy Neff; Woodie Zachry
Journal:  Pharmacoeconomics       Date:  2018-07       Impact factor: 4.981

5.  Resolution of ascites and hepatic encephalopathy and absence of variceal bleeding in decompensated hepatitis C virus cirrhosis patients.

Authors:  John Romano; Omar T Sims; Joshua Richman; Yuqi Guo; Tasnia Matin; Mohamed Shoreibah; Vishnu Kommineni; Krishna Venkata; Omar I Massoud
Journal:  JGH Open       Date:  2018-09-19

6.  Increasing Hospitalization Rates for Cirrhosis: Overrepresentation of Disadvantaged Australians.

Authors:  Elizabeth E Powell; Richard Skoien; Tony Rahman; Paul J Clark; James O'Beirne; Gunter Hartel; Katherine A Stuart; Steven M McPhail; Rohit Gupta; Peter Boyd; Patricia C Valery
Journal:  EClinicalMedicine       Date:  2019-06-13

Review 7.  Lights and Shadows in Hepatic Encephalopathy Diagnosis.

Authors:  Piero Amodio; Sara Montagnese
Journal:  J Clin Med       Date:  2021-01-18       Impact factor: 4.241

8.  Identifying and mitigating factors contributing to 30-day hospital readmission in high risk patient populations.

Authors:  Michael P Rogers; Paul C Kuo
Journal:  Ann Transl Med       Date:  2021-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.